Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Third Rock Launches Ember Therapeutics With Focus On Obesity And Type 2 Diabetes

Dec 15 2011

Related Content

Zafgen Obtains $33 Million In Series C Funds To Advance Anti-Obesity Drug In Phase II

Jul 07 2011

Third Rock Wise To The Opportunity In CNS; Stakes SAGE Therapeutics With $35 Million

Oct 18 2011

Related Companies

Takeda Pharmaceutical Co. Ltd.

Genentech, Inc.

Bristol Myers Squibb Company

Takeda Pharmaceutical Co. Ltd.

GSK plc

Orphan Disease Treatment Institute Co., Ltd.

Larimar Therapeutics, Inc.

Rhythm Pharmaceuticals, Inc.

Sage Therapeutics, Inc.

Additional Topics

United States Strategy Business Strategies BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window